PARP2

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Ovarian cancer, Immunotherapy, Carcinoma, Patient, SAN, Trial of the century, Abstract, CDX, AACR, PARP2, PDX, Pancreatic cancer, Safety, Stomach

P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.

Key Points: 
  • P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.
  • As an important downstream target of the STING signaling pathway, PARP7 is expected to be used in combination with immunotherapy in the future.
  • Details for the 2024 AACR abstracts are as follows:
    JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2.
  • The 2024 AACR Annual Meeting will be held in San Diego, California, U.S. from April 5th to April 10th.

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Partnership, Therapy, Impact, Food, PARP2, WRN, PARP1, EDT, Trial of the century, Science, Data analysis, Patient, Automation, Machine learning, TLR 7, Engineering, Eikon, Drug discovery, Morgan, AI, TLR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, VCP, Antiandrogen, Pharmaceutical industry, IND

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.

LYNPARZA Market Drug Insight and Market Forecast 2023 - 2032: Detailed Descriptions of Mechanism of Action, Dosage and Administration and R&D Progress - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Pharmaceutical, Health, Oncology, Mouse Models of Human Cancer database, Clinical trial, PARP, DNA repair, Food, News, DNA, PARP3, Pancreatic cancer, ADP, DDR, Disease, Maintenance, Gene, BRCA2, Research, United Kingdom, Patient, ATM, PARP1, Enzyme, Growth, EU4, HRR, Book, Desmoplastic small-round-cell tumor, PARP2, SWOT, Olaparib, Dietary supplement, Pharmaceutical industry, Vaccine, Medical imaging

The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • "LYNPARZA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LYNPARZA for Pancreatic Cancer in the seven major markets.
  • In the DDR pathways, LYNPARZA is being tested in a range of PARP-dependent tumor types with defects and dependencies.
  • The report provides insights into:
    A comprehensive product overview including the LYNPARZA description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.

Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress

Retrieved on: 
Saturday, September 10, 2022
Hedera, Drug development, Pharmacokinetics, C1-inhibitor, PARP2, MD, BeiGene, Neoplasm, Brain, Clinical trial, Barrow Neurological Institute, Oncology, PARP inhibitor, Protein, CNS, Traffic barrier, Hope, DNA, Glioblastoma, European Society for Medical Oncology, Time, LinkedIn, GLOBE, Instagram, Radiation, DNA repair, GBM, PARP1, Patient, Twitter, PARP, Pharmaceutical industry, Medical imaging, Facebook

The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.

Key Points: 
  • The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.
  • Nader Sanai, MD , Director of the Ivy Brain Tumor Center and Director of Neurosurgical Oncology at Barrow Neurological Institute, presented the findings during an oral session on CNS tumors at the European Society for Medical Oncology Congress in Paris today.
  • The initial results of this Phase 0 study of pamiparib plus radiotherapy are the first of its kind, said Dr. Sanai.
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter , and LinkedIn .

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Retrieved on: 
Tuesday, May 3, 2022
PLOS One, Scientific Reports, CD37, Mouse, B-cell lymphoma, Mantle cell lymphoma, PARP1, Company, Non-Hodgkin lymphoma, BRCA, Olaparib, Patient, PARP2, PLOS, Lymphoid leukemia, GMP, DNA, ADP, Publication, Cell death, Radioimmunotherapy, NHL, Research, Toxic epidermal necrolysis, PARP, Cell, Risk, PET, Vaccine, Medical imaging, Medical device

OSLO, Norway, May 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL).

Key Points: 
  • 1), reports on the combined effect of Humalutin with olaparib, a member of the class of anticancer therapies known as PARP inhibitors, on NHL cell lines.
  • In the studies, the combination of Humalutin and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma).
  • both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies.
  • Separately, Nordic Nanovector reports the publication of a paper in the high-impact open access journal Scientific Reports (Ref.

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Retrieved on: 
Tuesday, May 3, 2022
PLOS One, Scientific Reports, CD37, Mouse, B-cell lymphoma, Mantle cell lymphoma, PARP1, Company, Non-Hodgkin lymphoma, BRCA, Olaparib, Patient, PARP2, PLOS, Lymphoid leukemia, GMP, DNA, ADP, Publication, Cell death, Radioimmunotherapy, NHL, Research, Toxic epidermal necrolysis, PARP, Cell, Risk, PET, Vaccine, Medical imaging, Medical device

OSLO, Norway, May 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL).

Key Points: 
  • 1), reports on the combined effect of Humalutin with olaparib, a member of the class of anticancer therapies known as PARP inhibitors, on NHL cell lines.
  • In the studies, the combination of Humalutin and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma).
  • both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies.
  • Separately, Nordic Nanovector reports the publication of a paper in the high-impact open access journal Scientific Reports (Ref.

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Risk, Cell, ATHENA, Peptide, ATM, Time, Security (finance), Radiation, COVID-19, Company, Form, PARP2, TRT, Clovis Oncology, Sarcoma, Private Securities Litigation Reform Act, BRCA, Nuclear medicine, Therapy, Growth, PFS, Research, PARP3, Safety, Nivolumab, SSP, LLC, U.S. Securities and Exchange Commission, Review, Q4, Mesothelioma, Disclosure, Maintenance, CEO, Program, Ovarian cancer, Gallium, Insurance, Population, Drug, Neoplasm, International, NASDAQ, Cancer, PARP1, FAP, Sixth Street Partners, Antibody, Mutation, Isotope, Peritonitis, EMA, Patient, Form 8-K, Colon, Annual report, Clinical trial, Adult, FDA, SEC, Pharmaceutical industry, Medical imaging, Liquor, Internet service provider, Rucaparib, Database administrator, MCRPC, Rubraca (rucaparib), FAP-2286, Targeted Radionuclide Therapy, Clovis Oncology, RUBRACA (RUCAPARIB), FAP-2286, TARGETED RADIONUCLIDE THERAPY, CLOVIS ONCOLOGY

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.
  • Clovis reported a net loss for Q4 2021 of $64.4 million, or ($0.50) per share, and a net loss of $264.5 million, or ($2.29) per share, for FY 2021.
  • Similarly, net cash used in operating activities for FY 2021 was $196.1 million, compared with $252.7 million for FY 2020.
  • The accompanying condensed consolidated financial results have been prepared on a basis which assumes that Clovis will continue as a going concern.

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Retrieved on: 
Monday, January 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Exchange, Clinical trial, Safety, Cancer, Radiation, Form 8-K, Form, Gallium, PARP1, Colon, Neoplasm, View, Peritonitis, Database administrator, Drug, Security (finance), Antibody, Mutation, Patient, Isotope, Conference, Ovarian cancer, Adult, NASDAQ, Clovis Oncology, U.S. Securities and Exchange Commission, Insurance, BRCA, Peptide, Mesothelioma, Annual report, Program, PARP2, Rucaparib, Cell, CEO, Private Securities Litigation Reform Act, Company, FAP, Nuclear medicine, Sarcoma, PARP3, ATHENA, News, COVID-19, FDA, Therapy, Webcast, EMA, Population, Maintenance, Pharmaceutical industry, Medical imaging, Liquor, MCRPC, Rubraca (rucaparib), FAP-2286, Targeted Radionuclide Therapy, the LuMIERE Clinical Study, Clovis Oncology, RUBRACA (RUCAPARIB), FAP-2286, TARGETED RADIONUCLIDE THERAPY, THE LUMIERE CLINICAL STUDY, CLOVIS ONCOLOGY

Clovis Oncology , Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021.
  • The Company plans to report financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, February 23, 2022, before the open of the US financial markets.
  • Furthermore, we are in the process of finalizing our financial results for the fourth quarter and fiscal year 2021, and therefore our finalized and audited results and final analysis of those results are not yet available.
  • You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2021 based on the foregoing estimates.

Clovis Oncology Announces Third Quarter 2021 Operating Results

Retrieved on: 
Wednesday, November 3, 2021
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Safety, Head, Peptide, Neoplasm, U.S. Securities and Exchange Commission, Ovarian cancer, Radiation, Peritonitis, CAFS, International, Maintenance, Sixth Street Partners, Clinical trial, Isotope, COVID-19, PFS, ATM, Drug, Tumor microenvironment, SSP, Research, TRT, Mesothelioma, PARP3, Security (finance), Insurance, Private Securities Litigation Reform Act, Gallium, Annual report, Company, Nivolumab, Clovis Oncology, Form 8-K, Fibroblast, EMA, ATHENA, Antibody, Risk, LLC, FAP, CEO, PARP2, Population, BRCA, Patient, Colon, Form, Cancer, Mutation, NSCLC, PARP1, NASDAQ, FDA, Review, Time, Adult, Sarcoma, Cell, Therapy, Pharmaceutical industry, Lithium, Medical imaging, Liquor, Air cargo, Rubraca (rucaparib), FAP-2286, Targeted Radionuclide Therapy, Clovis Oncology, RUBRACA (RUCAPARIB), FAP-2286, TARGETED RADIONUCLIDE THERAPY, CLOVIS ONCOLOGY

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.
  • Clovis continues to expect selling, general and administrative expenses to decrease in the full year 2021 compared to 2020.
  • Clovis had $171.9 million in cash and cash equivalents as of September 30, 2021.
  • Net cash used in operating activities was $46.1 million for Q3 2021, down 15% from the $54.3 million reported in Q3 2020.

Global Advanced Gastric Carcinoma Pipeline Insights Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 4, 2021
Health, Oncology, News, Clinical trial, BeiGene, Mergers and acquisitions, II, SHR, Therapy, III, Stomach, Jiangsu Hengrui Medicine, PARP inhibitor, PARP2, HR, PARP1, Cancer, Discovery, Pharmaceutical industry, Coffee

The "Advanced Gastric Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advanced Gastric Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Advanced Gastric Carcinoma - Pipeline Insight, 2021 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D.
  • This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.